Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Heymach

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
JCO Precision Oncology|January 5, 2023
<i>HRAS</i> Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell CarcinomaNiamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Cancer Immunology Research|September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 5, 2013
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapyWilliam N William, Apar Pataer, Neda Kalhor, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Oncotarget|April 21, 2017
DNA methylation intratumor heterogeneity in localized lung adenocarcinomasKelly Quek, Jun Li, Marcos Estecio, et al.
British Journal of Cancer|January 15, 2019
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancerAndreas Varkaris, Anastasia Katsiampoura, Jennifer S Davis, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2018
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural MesotheliomaAnne S Tsao, Heather Lin, Brett W Carter, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
JCO Precision Oncology|January 5, 2023
<i>HRAS</i> Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell CarcinomaNiamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Cancer Immunology Research|September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 5, 2013
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapyWilliam N William, Apar Pataer, Neda Kalhor, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Oncotarget|April 21, 2017
DNA methylation intratumor heterogeneity in localized lung adenocarcinomasKelly Quek, Jun Li, Marcos Estecio, et al.
British Journal of Cancer|January 15, 2019
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancerAndreas Varkaris, Anastasia Katsiampoura, Jennifer S Davis, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2018
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural MesotheliomaAnne S Tsao, Heather Lin, Brett W Carter, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
Pageof 8